iStock/CasPhotography Martin Hoenigl, the President of the European Confederation of Medical Mycology, discusses the challenges of diagnosing and treating mucormycosis. Mucormycosis is perhaps not a term you were familiar with prior to the COVID-19 outbreak. However, the profile of this rare fungal disease has been rising in tandem with COVID-19 cases, particularly in under-resourced countries. Earlier this year, as the Delta variant of COVID-19 started to spread, cases of patients suffering from the so-called 'black fungus' began to mulitply, causing thousands of fatalities in its wake. While not the primary cause of the infection, physiological damage incurred as a result of COVID-19, and its consequential treatment, has triggered a surge in mucormycosis cases. Combined with issues around the availability of medical equipment and resources, medicine misuse, environmental exposure, and high levels of undiagnosed chronic diseases, many critically ill patients have...